Aveanna Q2 Revenue Up 13.7%, Raises 2026 Guidance
AVAH sits 53% above its 52-week low of $5.93.
Summary
Aveanna Healthcare reported Q2 2026 revenue of $670.5 million, up 13.7% year-over-year, and raised full-year 2026 revenue and Adjusted EBITDA guidance.
Key Events · Earnings and Guidance · AVAH
-
Q2 Revenue Up 13.7%
Revenue reached $670.5 million, up from $589.6 million in Q2 2025, driven by growth across all three segments.
-
Net Income Jumps 49%
Net income was $40.3 million, or $0.18 per diluted share, compared to $27.0 million, or $0.13 per share, a year ago.
-
Adjusted EBITDA Up 8%
Adjusted EBITDA was $95.4 million, up from $88.4 million, with margin of 14.2% of revenue.
-
Full-Year Guidance Raised
Revenue guidance increased to greater than $2.68 billion from $2.63-$2.65 billion; Adjusted EBITDA guidance raised to greater than $365 million from $338-$342 million.
Analysis · AVAH · Industrial Applications And Services
Aveanna delivered strong Q2 results with revenue up 13.7% and net income up 49% year-over-year. Management raised full-year revenue guidance to over $2.68 billion and Adjusted EBITDA to over $365 million, reflecting confidence in organic growth across all three segments. The company also highlighted improved liquidity with $97.2 million in cash and $110 million in incremental borrowing capacity. This is a positive earnings update that confirms the company's growth trajectory and operational momentum.
At the time of this filing, AVAH was trading at $9.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $5.93 to $10.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.